Is Matinas BioPharma stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Matinas BioPharma 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was $34.11, you would have made a loss of $-30.66 per share or -89.89%
No, the average daily trading liquidity for Matinas BioPharma is $29 675 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
Matinas BioPharma has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. Matinas BioPharma has a very good net profit margin of 2 121.62% and should have very high tolerances against inflation.
We have calculated the inflation risk for Matinas BioPharma to be low [0.45 of 1]
US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.